
Galliprant®
(grapiprant tablets)

TREATING CANINE OA



SHOULDN'T BE A PAIN

HOW TO INTEGRATE GALLIPRANT INTO AN EXPERT-RECOMMENDED,
STAGED APPROACH TO TREATMENT

INDICATION:

Galliprant controls pain and inflammation associated with osteoarthritis in dogs.

Elanco

TM

IF YOU'RE NOT PRESCRIBING GALLIPRANT FOR
OA INFLAMMATION, YOU'RE

PLAYING
WITH
FIRE



SKIP THE FLAMES AND GO STRAIGHT TO RELIEF WITH GALLIPRANT

Doesn't just mask pain; controls inflammation and pain at the source by targeting the EP4 receptor of PGE₂

Unique mode of action reduces the impact on organ health^{1,2}

Proven effective at improving pain interference, pain severity, quality of life and veterinary assessments¹

Safety of label dose supported by laboratory study in healthy dogs receiving ~15x the dose continuously for 9 months*

*No adverse event was serious enough to require removal from study. Treatment was associated with mild GI signs (soft stools with mucus and/or blood, vomiting) and mild, reversible decreases in total protein and albumin. There were no clinically significant changes in liver, kidney or coagulation parameters, or pathologic changes within the kidneys, liver or stomach.


IMPORTANT SAFETY INFORMATION: For use in dogs only. Keep this and all medications out of reach of children and pets to prevent accidental ingestion or overdose. Galliprant is a non-COX inhibiting NSAID. As a class, NSAIDs may be associated with gastrointestinal, kidney and liver side effects. Evaluation for pre-existing conditions and regular monitoring are recommended. Do not use in dogs that have a hypersensitivity to grapiprant. Concomitant use of Galliprant with other NSAIDs or corticosteroids should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. Owners should be advised to observe for signs of potential drug toxicity. Adverse reactions may include vomiting, diarrhea, decreased appetite, watery or bloody stools, and decreases in serum albumin and total protein. Please see product label or visit my.elanco.com/us/galliprant for full prescribing information.

RETHINK CANINE OSTEOARTHRITIS TREATMENT

PUBLISHED EXPERT TREATMENT GUIDELINES BY STAGE OF DISEASE^{3,4}

The first treatment guidelines specific to canine OA are now available.


Proposed Canadian consensus guidelines on osteoarthritis treatment based on OA-COAST stages 1–4.
Mosley C, Edwards T, Romano L, et al. *Front Vet Sci.* 2022;9:446.



COAST Development Group international consensus guidelines for the treatment of canine osteoarthritis.

Cachon T, Frykman O, Innes JF, et al. *Front Vet Sci.* 2023;10:1137888.

CORE TREATMENTS: UNANIMOUS EXPERT CONSENSUS



SECONDARY TREATMENTS^{3,4}


- Amantadine, gabapentin and cannabinoids should be reserved as secondary options after the recommended core treatments
- Due to limited evidence of beneficial effects and some quality and safety concerns, other joint supplements did not receive unanimous expert support

NSAID USE IN CANINE OSTEOARTHRITIS:

WHAT DO THE EXPERTS SAY?



MINIMUM OF THREE MONTHS OF DAILY NSAID THERAPY IS RECOMMENDED AT FIRST DIAGNOSIS



Even in mild stages of OA, a minimum of three months of daily NSAID therapy is recommended before determining if the dose can be tapered.




“It’s important to use NSAIDs long-term in dogs with OA, not just for 2 weeks or as needed. The goal isn’t intermittent pain relief. It’s to control pain and inflammation for a prolonged period.”

DENIS MARCELLIN-LITTLE, DEDV, DACVS, DECVS, ACVSMR

Dogs with moderate to severe OA are likely to require ongoing daily dosing for the long term.

INFLAMMATORY MEDIATORS PLAY A PIVOTAL ROLE IN OA PATHOGENESIS.⁵⁻⁷

INCREASED PGE2 IN THE JOINT LEADS TO:




GALLIPRANT IS AN IDEAL CHOICE FOR LONG-TERM TREATMENT

BECAUSE IT WORKS DIFFERENTLY FROM OTHER NSAIDS

“In our practice, Galliprant is a first-line, long-term NSAID because it doesn’t interfere with production of prostaglandins, and our considerable experience reflects its impressive safety data.”

MARK EPSTEIN, DVM, DABVP CANINE, DABVP FELINE, CVPP, DAAPM



“I think we’re lucky Galliprant came to the market because it has a different mode of action than previously available NSAIDs. It blocks OA pain and inflammation without disrupting production of prostaglandins.”


CAROLINA MEDINA, DVM, DACVSMR, CVA, CVPP

NSAIDS TREAT PAIN AND INFLAMMATION WHILE ANTI-NGF MABS PRIMARILY TREAT PAIN




“We diagnose dogs with OA after joint pathology has occurred, so there is already a moderate to highly inflammatory state in the joint. This should be addressed with NSAIDs first before considering adjunctive therapies such as blocking nerve growth factor, which targets pain sensation but is not directly anti-inflammatory so is reserved for later stages of OA.”

DAVID DYCUS, DVM, MS, CCRP, DACVS




OA BEGINS WITH CARTILAGE DAMAGE⁶



JOINT INFLAMMATION

TREATMENT:

- NSAIDs



NERVE SENSITIZATION

TREATMENT:

- NSAIDs
- Anti-NGF mAbs



ANTI-NGF MABS ARE NOT UNANIMOUSLY SUPPORTED BY EXPERTS UNTIL STAGES 3 AND 4 BECAUSE THEY TARGET PERIPHERAL SENSITIZATION BUT NOT THE UNDERLYING DRIVER, JOINT INFLAMMATION.^{3,4}

Despite effective analgesia, anti-NGF mAbs have been shown in multiple species to have a negative impact on cartilage, synovium and subchondral bone that may accelerate joint degeneration.^{8,9}




Although I am excited to have a new treatment targeting peripheral nerves, anti-NGF monoclonal antibodies won't replace NSAIDs in my practice because physiologically we know fluctuations in joint inflammation continue even in later stages of OA.”

DENIS MARCELLIN-LITTLE, DEDV, DACVS, DECVS, ACVSMR

GALLIPRANT: LONG-TERM RELIABILITY AND SAFETY

GALLIPRANT FEATURES A UNIQUE MODE OF ACTION THAT EFFECTIVELY ADDRESSES INFLAMMATION AND PAIN WHILE REDUCING THE IMPACT ON ORGAN HEALTH.

Masked, randomized, placebo-controlled, multicenter field trial in 285 client-owned dogs¹



IN A SEPARATE BUT SIMILAR STUDY, CARPROFEN SHOWED A SIMILAR DEGREE OF EFFICACY¹⁰:

45.6% OF TREATED DOGS CONSIDERED A SUCCESS AT DAY 14 VS 23.7% IN THE PLACEBO GROUP

Treatment Success =Improvement in pain severity score of 1 or more + Improvement in pain interference score of 2 or more + Overall assessment same or better

IN AN EARLY INTERVENTION STUDY¹¹, YOUNG DOGS* TREATED WITH GALLIPRANT CONTINUOUSLY FOR 4 MONTHS SHOWED SIGNIFICANT IMPROVEMENTS IN:



GAIT ANALYSIS[†]



MOBILITY



COMFORT



QUALITY OF LIFE



SLEEP QUALITY

EARLY INTERVENTION WITH GALLIPRANT AS PART OF A CORE TREATMENT PROTOCOL[‡] RESULTED IN SIGNIFICANT IMPROVEMENTS IN YOUNG DOGS WITH OA.

*Young dogs: 9-48 months

[†]Meaningful improvements in peak vertical force (force plate).

[‡]Study used three core treatments, unanimously recommended by experts: NSAIDs (Galliprant) to control joint pain and inflammation, an EPA-rich diet, and exercise.

EFFECTIVELY CONTROL CANINE OA INFLAMMATION AND PAIN AT THE SOURCE WITH GALLIPRANT

	Galliprant® (grapiprant tablets)	RIMADYL® (carprofen)	PREVICOX® (firocoxib)	LIBRELA® (bedinvetmab)
FDA approved to control pain associated with canine OA	●	●	●	●
FDA approved to control inflammation associated with canine OA	●	●	●	
Does not disrupt production of prostaglandins important for organ health ^{1,2}	●			●
Safety of the label dose supported by a laboratory study in healthy dogs receiving up to ~15x the dose daily for 9 months*	●			
Stocked by more veterinary clinics in the U.S. than any other brand name NSAID ¹²	●			

*No adverse event was serious enough to require removal from study. Treatment was associated with mild GI signs (soft stools with mucus and/or blood, vomiting) and mild, reversible decreases in total protein and albumin. There were no clinically significant changes in liver, kidney or coagulation parameters, or pathologic changes within the kidneys, liver or stomach.



TREATING CANINE OA SHOULDN'T BE A PAIN

- Galliprant is safe, effective, and easily given from the comfort of home without injections.
- It's a once-a-day, flavored chewable tablet that fits into your clients' daily routines.

See how a targeted approach to treating canine OA works. Visit my.elanco.com/us/galliprant or contact your Elanco sales representative at (800) 633-3796.

REFERENCES

- ¹Rausch-Derra L, Huebner M, Wofford J, Rhodes L. 2016. "A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis." J Vet Intern Med, 30.3: 756–763
- ²Kirby Shaw K, Rausch-Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016;2(1):3-9.
- ³Mosley C, Edwards T, Romano L, et al. Proposed Canadian Consensus Guidelines on Osteoarthritis Treatment Based on OA-COAST Stages 1–4. Frontiers in Veterinary Science. 2022 Apr 26; 9:830098.
- ⁴Cachon T, Frykman O, Innes JF, Lascelles BD, Okumura M, Sousa P, Staffieri F, Steagall PV, Van Ryssen B. COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis. Frontiers in Veterinary Science. 2023 Aug 3;10:1137888.
- ⁵Attur M, Al-Mussawir HE, Patel J, et al. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: Evidence for signaling via the EP4 receptor. J Immunol. 2008;181:5082-8.
- ⁶Tetlow LC, Adlam DJ, Wooley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage, associations with degenerative changes. Arthritis Rheum. 2001;44(3):585-94.
- ⁷Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2): 249-57.
- ⁸Wise BL, Seidel MF, Lane NE. The evolution of nerve growth factor inhibition in clinical medicine. Nature Reviews Rheumatology. 2021 Jan;17(1):34-46.
- ⁹Menges S, Michaelis M, Kleinschmidt-Dörr K. Anti-NGF treatment worsens subchondral bone and cartilage measures while improving symptoms in floor-housed rabbits with osteoarthritis. Frontiers in Physiology. 2023;14.
- ¹⁰Brown DC, Bell M, Rhodes L. Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. American Journal of Veterinary Research. 2013 Dec 1;74(12):1467-73.
- ¹¹Enomoto M, Hash J, et al. 2024. Response to Treatment with Grapiprant as Part of a Standard Multimodal Regimen in Young Dogs with Appendicular Joint Osteoarthritis-Associated Pain. Front. Vet Sci. 11:1-10.
- ¹²Elanco Animal Health. Data on file.

Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
Other product names are trademarks of their respective owners. ©2025 Elanco or its affiliates. PM-US-25-0718

Elanco
TM